Kairos Pharma Ltd. (KAPA)
AMEX: KAPA
· Real-Time Price · USD
1.19
-0.05 (-4.03%)
At close: Aug 15, 2025, 3:59 PM
1.22
2.68%
Pre-market: Aug 18, 2025, 06:20 AM EDT
Kairos Pharma Income Statement
Financials in USD. Fiscal
year is
January - December.
| Fiscal Year | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 |
| Period Ending | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 |
Revenue | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost of Revenue | 160K | 160K | 160K | 160K | 160K | 120K | 80K | 40K | n/a | n/a | n/a | n/a | n/a | n/a |
Gross Profit | -160K | -160K | -160K | -160K | -160K | -120K | -80K | -40K | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Income | -4.55M | -3.32M | -2.34M | -1.98M | -1.89M | -1.88M | -1.71M | -805K | -642K | -550K | -571K | -391K | -267K | -147K |
Interest Income | 38K | 4K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Pretax Income | -4.71M | -3.54M | -2.6M | -2.74M | -2.01M | -1.99M | -1.81M | -890K | -812K | -961K | -1.05M | -854K | -620K | -235K |
Net Income | -4.71M | -3.54M | -2.6M | -2.74M | -2.01M | -1.99M | -1.81M | -890K | -812K | -961K | -1.05M | -854K | -620K | -235K |
Selling & General & Admin | 3.3M | 2.46M | 1.76M | 1.57M | 1.46M | 1.51M | 1.55M | 642K | 552K | 490K | 484K | 352K | 228K | 114K |
Research & Development | 1.18M | 742K | 414K | 249K | 268K | 241K | 82K | 123K | 90K | 60K | 87K | 39K | 39K | 33K |
Other Expenses | -38K | 120K | 160K | 160K | 160K | 120K | 80K | 40K | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Expenses | 4.43M | 3.32M | 2.34M | 1.98M | 1.89M | 1.88M | 1.71M | 805K | 642K | 550K | 571K | 391K | 267K | 147K |
Interest Expense | 797K | 828K | 864K | 760K | 121K | 114K | 98K | 69K | 154K | 395K | 463K | 463K | 353K | 88K |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 4.47M | 3.32M | 2.34M | 1.98M | 1.89M | 1.88M | 1.71M | 805K | 642K | 550K | 571K | 391K | 267K | 147K |
Income Tax Expense | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Shares Outstanding (Basic) | 17.21M | 15.88M | 13.74M | 10.91M | 12.84M | 10.56M | 10.47M | 11.22M | 10.33M | 10.33M | 10.34M | 10.25M | 10.18M | 10.18M |
Shares Outstanding (Diluted) | 17.21M | 15.88M | 13.74M | 10.91M | 12.84M | 10.56M | 10.47M | 11.22M | 10.33M | 10.33M | 10.34M | 10.25M | 10.18M | 10.18M |
EPS (Basic) | -0.33 | -0.27 | -0.22 | -0.26 | -0.19 | -0.19 | -0.17 | -0.08 | -0.08 | -0.09 | -0.1 | -0.08 | -0.06 | -0.02 |
EPS (Diluted) | -0.33 | -0.27 | -0.22 | -0.26 | -0.19 | -0.19 | -0.17 | -0.08 | -0.08 | -0.09 | -0.1 | -0.08 | -0.06 | -0.02 |
EBITDA | -4.41M | -3.13M | -2.12M | -2.36M | -1.73M | -1.72M | -1.55M | -645K | -482K | -390K | -411K | -271K | -187K | -107K |
EBIT | -4.45M | -3.25M | -2.28M | -2.52M | -1.89M | -1.88M | -1.71M | -805K | -642K | -550K | -571K | -391K | -267K | -147K |
Depreciation & Amortization | 120K | 160K | 160K | 160K | 160K | 160K | 160K | 160K | 160K | 160K | 160K | 120K | 80K | 40K |